Cinacalcet for secondary hyperparathyroidism
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000799
English, French
Authors' objectives:
To summarize the available information on the use of cinacalcet (Trade Name: Sensipar, manufactured by Amgen Inc.) for the treatment of secondary hyperparathyroidism.
Authors' recommendations:
Cinacalcet will likely be most widely used to treat secondary hyperparathyroidism related to kidney disease. Although it improves physiologic outcomes, there is a lack of evidence to assess its impact on clinical outcomes such as death, bone disease, and cardiovascular events. A pharmacoeconomic analysis would further define its role.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Kidney Diseases
- Hyperparathyroidism
- Hyperparathyroidism, Secondary
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.